Echo trial result on new hormonal contraception, a contraceptive option, and HIV risk (called ECHO study) is expected to be released mid year, statement from FP2020 reveals.
The new hormonal contraception will help guide the implementation of safe, effective policies and services that will enable women at high risk of HIV to make fully informed choices about contraception and HIV prevention.
The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study is an open-label, randomized, clinical trial comparing three highly effective, reversible methods of contraception — the progestogen-only injectable depot-medroxyprogesterone acetate (DMPA), a levonorgestrel implant, and the non-hormonal copper intrauterine device — to evaluate whether there is any difference in the risk of acquiring HIV infection among users of these methods.
To further enlighten the public more on the ECHO study, a Webinar will hold on Tuesday, April 2 and it will feature:
- Beth Schlachter, Executive Director, FP2020
- Dr. Jared Baeten, Vice Chair, Department of Global Health, University of Washington, ECHO Consortium
- Dr. Nelly Mugo, Research Associate Professor, Global Health, University of Washington, ECHO Management Committee
- Tamar Abrams, Communications Director, FP2020